NewsRoom Articles - Page 59 of 154 - PsychedelicNewsWire (PNW)

FridayMay 13, 2022 2:31 pm

Wesana Health Could Divest Itself of All Assets Except Drug-Development Unit

Last week, Wesana Health announced that it was considering selling its assets under the division focused on care delivery, which includes its psychedelic therapy clinics. In its press release, the integrated life science company stated that it was planning to focus on its drug-development division. Before making this announcement, the company was focused on the development of new therapies and delivering new care. Wesana Health is now considering selling its communication platform for psychedelic practitioners, known as PsyTech Connect, and its platform, which was designed to improve clinical protocols, known as Wesana Solutions. This is in addition to plans to…

ThursdayMay 12, 2022 1:55 pm

Compass Pathways Research Suggests Psilocybin Can Treat Anorexia

Recently released findings from a study show that the psilocybin therapy developed by Compass Pathways PLC (NASDAQ: CMPS) may be used to treat anorexia. The therapy in question, COMP 360, was primarily developed to treat depression. Anorexia or anorexia nervosa is an eating disorder in which individuals have abnormally low weight caused by restricting food intake and an extreme fear of gaining weight. Psychiatrist Katherine A. Halmi believes that this eating disorder stems from the ego, explaining that the severity of the core features of the disorder, including preoccupations with exercising, eating, weight and body image, forecast higher resistance to…

WednesdayMay 11, 2022 11:57 am

Study Indicates People Are Cautious About Psilocybin Therapy, More Awareness Needed

A new study has found that individuals are cautious about the use of psilocybin-assisted psychotherapy in the treatment of depression. Psilocybin is an active chemical found in magic mushrooms. This mind-altering compound may influence how individuals experience the world by inducing changes in the sense of self as well as a user’s perception of time, sensory perception and mood. Preliminary studies have shown that administering psilocybin in conjunction with psychotherapy can bring about improvements for patients afflicted by depression. The researchers’ objective was to look into individuals’ perceptions of psilocybin-assisted therapy in comparison to their perceptions of cognitive-behavioral therapy, which…

WednesdayMay 11, 2022 11:15 am

Silo Pharma Inc. (SILO) Spotlight: Ketamine

Ketamine shows promise in treating Alzheimer’s Disease, Parkinson’s Disease as well as depression, suicide ideation and more In 2021, Silo Pharma (OTCQB: SILO) entered into a joint venture with Zylö Therapeutics to “explore the clinical development of ketamine using ZTI’s Z-pod (transdermal) technology.” This innovative technology allows Silo, an early-stage biopharmaceutical company, to develop a ketamine delivery system for those suffering dysphagia, a difficulty or complete inability to swallow.(1) Silo Pharma is exploring the efficacy of ketamine in treating patients suffering from both Alzheimer’s Disease (“AD”) and Parkinson’s Disease (“PD”). Over 80% of PD patients(2) and 75% of AD patients(3)…

TuesdayMay 10, 2022 3:27 pm

Survey Discovers That Psilocybin Is Relatively Safe Drug

Findings from a large survey propose that psilocybin is a relatively safe drug, with less than 1% of users of psilocybin mushrooms seeking emergency medical care after consumption. The survey’s findings, which also propose that adverse incidents resulting in emergency medical care are often psychological in nature and can be resolved in 24 hours, were reported in the “Journal of Psychopharmacology.” Psilocybin, which is the active ingredient found in hallucinogenic mushrooms, is known to induce a mind-altering state when consumed. While this compound is considered safe in comparison to other psychoactive substances, it can still cause adverse reactions such as…

MondayMay 09, 2022 1:52 pm

3 Psychedelic Documentaries You Can Watch on YouTube

New articles on psychedelic substances and their numerous uses in the field of medicine are being published every day in different parts of the world. As researchers discover more about psychedelics and the numerous benefits they hold, interest in these substances is growing. If you aren’t keen on reading medical journals to learn more about psychedelics but you’d still like to know more, here are some psychedelic documentaries you can watch on YouTube. True Hallucinations This experimental film, which is almost three hours long, is a tribute to the late philosopher Terence McKenna. McKenna spoke on and wrote about various…

FridayMay 06, 2022 12:18 pm

New Psychedelic Therapy Center Launched in Texas

Data from the National Institute on Drug Abuse shows that millions of individuals in America have already battled or will battle addiction to drugs, with 85% of them relapsing within one year of treatment. A recently launched program is hoping to lower this number significantly. The program, which was launched in Austin, Texas, will be administering ketamine therapy to eligible patients. The center, which has been christened Within, plans to combine psychedelic medicine with functional wellness and holistic healing in the treatment of addictions and mental disorders, including depression, post-traumatic stress disorder and substance abuse. Ryan Saldanha, a resident of…

FridayMay 06, 2022 9:00 am

Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Proprietary CYB003 Set to Move Forward in First-in-Human Phase 1/2a Clinical Trial

Cybin has selected Clinilabs Drug Development Corporation as CRO for its Phase 1/2a clinical trial evaluating CYB003 for treating major depressive disorder (“MDD”) MDD impacts more than 264 million people worldwide, is a leading cause of mental disability worldwide Preclinical studies show CYB003 may have significant advantages over classic psilocybin In a significant step forward in the study of alternative treatments for major depressive disorder, Cybin (NEO: CYBN) (NYSE American: CYBN) is moving forward in its phase 1/2a clinical trial of its proprietary deuterated psilocybin, CYB003 (https://ibn.fm/VTjoI). Based on previous research, CYB003 has the potential to effectively treat MDD with significant…

ThursdayMay 05, 2022 2:19 pm

Tesla CEO Elon Musk Believes Psychedelics Are Better Than Pharmaceutical Medications

Tesla CEO Elon Musk recently stated on Twitter that psychedelic substances and other plant-based drugs were effective as treatments for a number of mental health conditions. Musk has in the past smoked a joint during a livestream video. The tweet in question is an excerpt from a conversation between a pair of Twitter users, one of whom referred to a feature on the New York Times, which discussed Adderall. The other user replied to the tweet, noting that prescribed psychedelic drugs would soon replace selective serotonin reuptake inhibitors (SSRIs) and amphetamines, probably in the next decade. SSRIs are antidepressants commonly…

WednesdayMay 04, 2022 3:40 pm

Studies Find Link Between ADHD, Fibromyalgia

Various studies have found a link between fibromyalgia and ADHD, with some urging clinicians to evaluate the presence of attention deficit hyperactivity disorder (ADHD) in individuals who have a history of fibromyalgia. ADHD is a condition characterized by persistent impulsivity, hyperactivity, impaired concentration and inattention, as well as disorganized behavior, anxiety and emotional instability. The CDC estimates that while more than 8% of children have been diagnosed with this condition thus far, less than 1% of adults have received the same consideration. Fibromyalgia is a chronic pain disorder linked to modified activity of the neurotransmitters involved in pain sensitivity, with…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000